{"type":"trials","record":{"id":21790,"source_id":"clinicaltrials-gov","external_id":"NCT06907329","title":"The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.","brief_summary":"The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.","overall_status":"Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Qing Su","enrollment":126,"countries":["China"],"start_date":"2025-06-05","completion_date":"2027-03-31","last_update_date":"2025-07-08","source_url":"https://clinicaltrials.gov/study/NCT06907329","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:10.338673+00:00","last_seen_at":"2026-09-25T07:05:20.248+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 70 Years","comparator":"Placebo Arm","organization":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","interventions":["NMN","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["CD3+CD8+CD27-CD28- T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","Body composition analysis, expressed in kg, %, and g/cm², evaluated by dual-energy X-ray absorptiometry — 26 weeks","Determination of fasting blood glucose and OGTT 2-hour blood glucose, expressed in mmol/L, evaluated by glucose oxidase…","CD3+CD8+CD27- T cells as a percentage of total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD28- T cells as a percentage of total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD27- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD28- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD27-CD28- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD45RA+CCR7- T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD57+KLRG1+ T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+ T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","NMN, NAD+ levels in peripheral blood cells, evaluated by mass spectrometry — 26 weeks","Peripheral blood cell telomere length, expressed as a unitless value , evaluated by Quantitative Real-time polymerase c…","Cardiorespiratory fitness related indicators, expressed in mL/kg/min, L/min, beats/min, and unitless ratios, evaluated…","Glycosylated hemoglobin, expressed in mmol/mol, evaluated by HPLC — 26 weeks","Pancreatic β-cell function, expressed as a unitless value, evaluated by HOMA-β、HOMA-IR — 26 weeks","Weight, expressed in kilograms, evaluated by weighing scale — 26 weeks","Waist circumference, expressed in centimeters, evaluated by tape measure — 26 weeks","Waist-to-hip ratio, expressed as a unitless ratio, evaluated using a standardized tape measure following WHO measuremen…","Waist-to-height, expressed as a unitless ratio, evaluated using a standardized tape measure following WHO measurement p…"],"design_description":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","source_has_results":false},"controlled_terms":["Immunosenescence","Metabolism","NMN","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: nicotinamide mononucleotide.","quality_checked_at":"2026-09-25T07:05:30.295959+00:00","duplicate_cluster_key":"id:nct06907329","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-06-05 to 2027-03-31","comparator":"Placebo Arm","confidence":"structured-source","population":"ALL · 50 Years to 70 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T07:05:20.300Z","intervention":["NMN","Placebo"],"participants":126,"study_design":"RANDOMIZED · PARALLEL · OTHER · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["CD3+CD8+CD27-CD28- T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","Body composition analysis, expressed in kg, %, and g/cm², evaluated by dual-energy X-ray absorptiometry — 26 weeks","Determination of fasting blood glucose and OGTT 2-hour blood glucose, expressed in mmol/L, evaluated by glucose oxidase…","CD3+CD8+CD27- T cells as a percentage of total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD28- T cells as a percentage of total CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD27- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD28- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD4+CD27-CD28- T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD45RA+CCR7- T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+CD57+KLRG1+ T cells as a percentage of CD3+CD8+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","CD3+CD8+ T cells as a percentage of CD3+CD4+ T cells, expressed in %, evaluated by flow cytometry — 26 weeks","NMN, NAD+ levels in peripheral blood cells, evaluated by mass spectrometry — 26 weeks","Peripheral blood cell telomere length, expressed as a unitless value , evaluated by Quantitative Real-time polymerase c…","Cardiorespiratory fitness related indicators, expressed in mL/kg/min, L/min, beats/min, and unitless ratios, evaluated…","Glycosylated hemoglobin, expressed in mmol/mol, evaluated by HPLC — 26 weeks","Pancreatic β-cell function, expressed as a unitless value, evaluated by HOMA-β、HOMA-IR — 26 weeks","Weight, expressed in kilograms, evaluated by weighing scale — 26 weeks","Waist circumference, expressed in centimeters, evaluated by tape measure — 26 weeks","Waist-to-hip ratio, expressed as a unitless ratio, evaluated using a standardized tape measure following WHO measuremen…","Waist-to-height, expressed as a unitless ratio, evaluated using a standardized tape measure following WHO measurement p…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"immune-aging","is_published":true,"match_reasons":["Title contains controlled term: immunosenescence.","Abstract contains controlled term: immunosenescence.","Source terminology contains: immunosenescence.","Title supplies longevity context: senescence, elderly.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Immune ageing","slug":"immune-aging"}},{"topic_slug":"nad-metabolism","is_published":true,"match_reasons":["Title contains controlled term: nicotinamide mononucleotide.","Abstract contains controlled term: nicotinamide mononucleotide, nmn.","Source terminology contains: nmn.","Title supplies longevity context: senescence, elderly.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"NAD metabolism","slug":"nad-metabolism"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/21790","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}